Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.

Buyer framework

How to Evaluate a Telehealth GLP-1 Provider: A 7-Point Framework

Edited by Gabriel BrocklesbyFounder & EditorFact-checkedLast updated 28 July 2026

Telehealth GLP-1 access is widely available now, but provider quality varies far more than the marketing suggests. Pricing pages look similar. Promises look similar. The real differences live in clinical oversight, prescribing standards, and what happens after the first month. This guide gives you a 7-point evaluation framework to apply before you sign up — and applies it to three representative providers as worked examples.

The 7-Point Framework

Apply these seven points to any telehealth GLP-1 provider before paying for an intake. The first three filter out providers that shouldn't exist; the next four separate providers that look similar on the surface.

1. Clinician credentials and oversight

Ask whether a licensed clinician is actually reviewing your intake — not just a software workflow rubber-stamping a checkbox form. Strong providers name their medical leadership publicly, list the states where their clinicians are licensed, and explain how follow-up consultations are handled. If you can't find a named clinician anywhere on the provider's site, treat that as a signal to keep looking.

2. Eligibility transparency

Look for clear, up-front statements about who qualifies — BMI thresholds, age ranges, contraindications, and conditions that automatically rule someone out. Vague eligibility language like 'our clinicians will assess if treatment is right for you' is a flag. You should be able to know if you'll likely be denied before paying for an intake.

3. Pricing clarity beyond the first month

The published monthly price should include medication, clinician review, and shipping. If labs, refills, dose changes, or follow-up consultations cost extra, the real monthly cost is higher than advertised. The cheapest providers are sometimes the cheapest because they unbundle aggressively. Ask explicitly: what does the month-two-onwards price actually cover?

4. Medication route and pharmacy sourcing

Compounded semaglutide, brand-name Wegovy, or both? Compounded has historically been lower-cost, but its availability is now limited and legally uncertain — the FDA declared the semaglutide (Feb 2025) and tirzepatide (Oct 2024) shortages resolved, which ended routine compounding of copies, and an April 2026 FDA proposal would restrict it further (final determination pending). Where a provider still offers a compounded option, ask which pharmacy it uses, whether it is 503A or 503B registered (the FDA categories for compounding), and what quality controls and legal basis are in place. For brand-name Wegovy, confirm the medication is dispensed through a licensed retail or specialty pharmacy.

5. Refill cadence and dose progression

How are refills triggered — automatically each month, or after a clinician check-in? How is dose increase decided — by you, by the clinician, or by a default schedule? A provider that ships month after month with no contact is treating GLP-1 as a subscription rather than supervised medical care. Strong providers build in regular touchpoints, especially in months one through four when dose escalation typically happens.

6. Side-effect handling and clinician access

What happens when you experience nausea, fatigue, constipation, or anything more serious? Is there a clinician messaging channel? What's the response time? Can you switch medications or pause without losing your money? Side effects are the rule, not the exception, with GLP-1 treatment. A provider with weak or slow side-effect channels will leave you stranded mid-dose.

7. Cancellation, refund, and continuity

Can you stop the program if it's not working? Are unused medications refundable or transferrable? Are you locked into an annual contract? What happens to your medical record and dose history if you switch providers? GLP-1 programs are not one-month commitments — find out the exit terms before the entry terms.

Regulatory note: After the FDA declared the semaglutide shortage resolved in February 2025, pharmacies could no longer routinely compound copies of that licensed product. On 1 May 2026 the FDA published a notice proposing not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List; a final determination is still pending. The availability and pricing described here may not reflect what a provider can currently supply, so confirm the current offering and cost directly with any provider before relying on it.Last reviewed: July 2026

Source: FDA — Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) · United States · Decision 21 February 2025

Source: FDA — Federal Register notice — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B · United States · Published 1 May 2026

Framework Applied: Three Providers

Three representative providers from different positions in the market. No provider scores highest on all seven points — they're optimising for different priorities. Below is how each scores against the framework.

bmiMD applied

Board-certified physicians — not nurse practitioners or PAs — run the prescribing review, with same-day telehealth consultations usually available. Strong on the point that matters most.
Standard GLP-1 eligibility assessed by a clinician at intake, and treatment access depends on that review. bmiMD states that treatment is available across all 50 states; PCF has not independently verified state-by-state availability.
Starting prices are advertised on bmiMD's site — compounded semaglutide from $119/mo and tirzepatide from $179/mo when checked in September 2026 — and FSA/HSA is accepted. Both are “starting as low as” entry rates, so confirm the ongoing cost and what the lower rate requires before comparing.
Compounded semaglutide and tirzepatide where clinically appropriate; the partner pharmacy isn't named publicly, so sourcing is less transparent than providers that disclose it.
Dose and protocol are personalised with physician oversight rather than a fixed single pathway; standard US shipping is included on eligible paths.
Unlimited messaging with the prescribing provider plus 24/7 portal access — strong coverage if side effects appear mid-programme.
3-month programmes bundle wellness coaching; confirm exact cancellation terms during intake, as they aren't published publicly.

Overall: bmiMD scores highest on clinician depth — board-certified physicians, same-day consults, and unlimited provider messaging cover the two framework points that matter most for GLP-1 (oversight and side-effect handling). It's weaker on sourcing transparency, since the partner pharmacy only surfaces during intake, and its advertised prices are entry rates whose terms are not stated alongside them. The strong pick if physician access and personalisation are what you are optimising for.

Full profile

bmiMD

Personalised weight loss (compounded GLP-1)

A weight-loss programme that emphasises personalisation — dose and protocol tailored to patient profile rather than a single-pathway approach. Board-certified physicians provide same-day telehealth consultations with unlimited messaging. 80,000+ members claimed, 4.9-star self-reported rating.

Review bmiMD

Best for: Patients who want a board-certified physician evaluation and same-day telehealth consultation with unlimited messaging access, especially those who have tried other GLP-1 programmes and want more clinical depth or personalisation.

Pricing: Starting prices are advertised publicly on bmiMD's website. On 5 September 2026 the site showed compounded semaglutide from $119 per month and compounded tirzepatide from $179 per month, each listed as a “starting as low as” rate against a higher struck-through figure. FSA/HSA accepted. 3-month programmes include wellness coaching. Prices change — confirm the current rate before starting.

10% off a new programme — code GOALS10

Board-certified physicians on the prescribing team
Same-day telehealth consultations available
Unlimited messaging with the prescribing provider
80,000+ members
4.9-star self-reported rating

Review bmiMD Read profile

Ro applied

Large telehealth platform with a broad clinician network; less personal than smaller providers, but scale lends credibility.
BMI-based eligibility; brand-name Wegovy pathways subject to insurance and supply.
$39 membership plus medication costs that vary significantly by insurance and brand vs compounded; less straightforward at a glance.
Both brand-name Wegovy and compounded options where appropriate; pharmacy sourcing is platform-wide.
Standard automatic refill with clinician check-ins at intervals.
Platform messaging via the Ro app; response times typical for large telehealth platforms.
Membership-based, cancellable monthly.

Overall: Ro scores highest on brand familiarity and brand-name medication access, less differentiated on care depth. The right pick if you specifically want Wegovy and have insurance to navigate, or if you value the trust signal of a recognised consumer-health brand.

Full profile

Ro.co

Large telehealth brand

Ro is one of the strongest brand-led comparison anchors in online weight-loss search. Its Ro Body membership pairs provider-led GLP-1 care with an insurance concierge that pursues coverage on the patient's behalf.

Review Ro

Best for: People who want a familiar, well-known digital-health brand with insurance-aware GLP-1 pathways and the option to pursue coverage rather than pay full cash price.

Pricing: Ro Body membership is $39 for the first month, then $149/month — or as low as about $74/month when prepaid annually. GLP-1 medication is billed separately: oral Wegovy (semaglutide) from around $149/month and Zepbound (tirzepatide) vials from around $299/month cash-pay. An insurance concierge pursues coverage, so eligible patients may pay closer to a copay.

Major consumer-health brand
Insurance concierge pursues GLP-1 coverage
Membership from $39 the first month

Review Ro Read profile

SHED applied

Licensed clinician review with each intake; less brand-established than larger players.
BMI-based eligibility; cash-pay positioning is reasonably transparent.
Starting prices vary by medication route — confirm exact monthly cost before committing.
Multiple compounded options including non-injection routes on some plans; route flexibility is the strongest differentiator.
Standard cash-pay monthly cadence.
Clinician messaging available.
Cash-pay structure makes cancellation simple.

Overall: SHED scores highest on medication route flexibility, average on pricing transparency (routes change the math). The right pick if you have a strong preference for non-injection options or want to compare cash-pay budget tiers.

Full profile

SHED

Online GLP-1 program

SHED is a value-led online GLP-1 provider with multiple medication routes available. A reasonable comparison option when affordability is the primary driver and cash-pay structure is acceptable.

Review SHED

Best for: Cash-pay users comparing flexible medication routes on price.

Pricing: Starting prices vary by medication route; confirm full monthly cost before purchase

Cash-pay value positioning
Multiple medication routes
Variable pricing by route — verify before purchase

Review SHED Read profile

How to Use This Framework

No provider scores highest on all seven points. The framework's job isn't to pick one winner — it's to make sure you don't sign up to a provider that fails on the points you actually care about. Pick the three or four framework points that matter most for your situation, then evaluate providers against those. If you want to compare the full provider set side by side, the GLP-1 providers comparison shows all options without the framework lens.

Next step

Want help choosing? Tell us your goal and we'll point you to listed options

Answer a few quick questions and we'll match you with listed clinics and programs that fit — free, no obligation.

Get matched with options

Frequently asked questions

Which framework point matters most?

Depends on your situation. For first-time GLP-1 users, clinician oversight (#1) and side-effect handling (#6) matter most because the first three months are the highest-risk window. For longer-term users, refill cadence (#5) and continuity (#7) matter more.

What if a provider doesn't pass on a specific framework point?

Some failures are dealbreakers — no named clinician, no side-effect channel. Others are tradeoffs you can live with — less brand familiarity, slightly opaque pricing. Pick which failures you can tolerate before signing up.

How do I find this information about a provider?

The marketing site rarely has all of it. Read the FAQ pages, terms of service, and any 'medical team' or 'about' pages. Search Reddit, Trustpilot, and the BBB for refund and cancellation stories. Email the provider directly and time their response — slow pre-sales response usually means slow post-sales response.

Should I avoid providers that fail on multiple framework points?

Usually yes, but which points matter. A provider failing on points 1 (clinician credentials) and 6 (side-effect handling) is a hard no for GLP-1 specifically. A provider failing on 3 (pricing clarity) and 7 (cancellation) is annoying but survivable if the medical fundamentals are strong.

Is this framework only for GLP-1, or other peptide treatments too?

GLP-1 specifically. Other peptides have different regulatory contexts and evaluation criteria. For broader peptide therapy provider research, browse the clinic directory.